Elevance Health (ELV) is back in focus after strong fourth quarter earnings, a higher dividend, updated full year guidance, and a flurry of senior appointments across its Health Benefits and Carelon units.

The recent leadership reshuffle, strong fourth quarter results, higher dividend, and updated guidance have helped the share price rebound, with a 7 day share price return of 5.01% and a 30 day share price return of 4.98%. However, the 1 year total shareholder return decline of 28.38% and 5 year total shareholder return decline of 10.60% point to longer term underperformance and fading momentum.

If Elevance Health's earnings and leadership news has your attention, it can be useful to compare it with other healthcare names using our screener for 36 healthcare AI stocks

With Elevance Health trading at $300.74, an implied 27% discount to analyst targets of around $381 and a value score of 6, the key question is whether the recent weakness offers an entry point or whether the market is already pricing in future growth.

Most Popular Narrative: 23% Undervalued

According to the most followed narrative, Elevance Health's fair value sits at $390.54 versus the last close of $300.74, implying meaningful upside in the model before the latest price recovery.

As a potential growth investment, Elevance Health offers a compelling mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. While near-term risks like Medicaid enrollment declines and cost pressures pose challenges, its diversified revenue base and focus on innovation provide resilience.

Curious what supports that higher fair value? The narrative leans on steadier earnings expansion, firmer margins, and a future profit multiple that assumes Elevance can narrow the gap with larger peers.

Result: Fair Value of $390.54 (UNDERVALUED)

However, that upside view still hinges on Elevance containing medical costs and stabilising Medicaid membership pressures, which previously weighed on earnings and valuation.

Next Steps

All this leaves the mood mixed, so do not wait for consensus. Instead, check the data yourself and weigh what matters most to you with 5 key rewards

Ready for more investment ideas?

If Elevance Health has sharpened your focus, do not stop here. Use the Simply Wall St Screener to quickly spot fresh opportunities that match your style.

• Target resilient compounders by scanning companies with strong finances and steady profiles using our 68 resilient stocks with low risk scores
• Hunt for quality at a discount by checking out companies trading below their estimated worth through the 59 high quality undervalued stocks
• Lock in potential income streams by reviewing companies with robust payouts inside the 13 dividend fortresses

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.